GB-13 / Targepeutics - LARVOL DELTA

Discovery, validation and deployment of a molecular signature of vulnerability to GB13 in an early stage GBM clinical trial (SNO 2025) - "The size of GB13 (79kDa) warrants direct intracranial convection enhanced delivery (CED), further contributing to minimal systemic exposure while maximally addressing the tumor field. Parameters of delivery volume, catheter placement, and subsequent assessment of drug distribution, as well as induced cell death related to abundance of IL13Ra2 expression and genes driving golgi-to-ER retrograde traffic / transport will be analyzed for prediction of response in this early stage trial as part of the NCI Glioblastoma Therapeutics Network."

Clinical • Brain Cancer • Glioblastoma • Glioma • Solid Tumor • IL13 • IL13RA2

Discovery, validation and deployment of a molecular signature of vulnerability to GB13 in an early stage GBM clinical trial (WFNOS 2025) - "The size of GB13 (79kDa) warrants direct intracranial convection enhanced delivery (CED), further contributing to minimal systemic exposure while maximally addressing the tumor field. Parameters of delivery volume, catheter placement, and subsequent assessment of drug distribution, as well as induced cell death related to abundance of IL13Ra2 expression and genes driving golgi-to-ER retrograde traffic / transport will be analyzed for prediction of response in this early stage trial as part of the NCI Glioblastoma Therapeutics Network."

Clinical • Brain Cancer • Glioblastoma • Glioma • Solid Tumor • IL13 • IL13RA2

GB13 is a potent neoadjuvant treatment option for IL13Ra2-expressing GBM and improves standard-of-care therapy (SNO 2024) - "Despite maximum safe surgical resection followed by radiation and temozolomide chemotherapy, current median survival is 14-18 months...Preclinical models support the use of GB13 prior to radiation for decreased tumor proliferation. Using multiple models, our results identify a temporal benefit for treating GBM tumors prior to IR and this should be tested in future clinical studies."

Clinical • Diffuse Midline Glioma • Glioblastoma • Malignant Glioma • Pediatrics • IL13RA2

GB13 is a potent treatment for IL13Ra2-expressing GBM and DMG and improves standard-of-care therapy (SNO 2023) - "Finally, we determined that GB13 works in concert with clinical standard-of-care radiation therapy to increase cell death, compared to radiation alone. Based on this work, we and our clinical collaborators are confident that the current work confirms GB13 has many important characteristics as an exciting therapy, which continues development towards a Phase I clinical trial for both GBM and pediatric DMG."

Brain Cancer • CNS Tumor • Diffuse Midline Glioma • Glioblastoma • Glioma • Oncology • Pediatrics • Solid Tumor • IL13 • IL13RA2

Efficacy of convection-enhanced delivery of GB-13 (IL13.E13K-PE4E) in an orthotopic xenograft model of high-grade glioma is predicated on IL-13Rα2 expression. (ISPNO 2022) - No abstract available

Preclinical • Brain Cancer • Glioma • Oncology • Solid Tumor • IL13

Efficacy of convection-enhanced delivery of GB-13 (IL13.E13K-PE4E) in an orthotopic xenograft model of high-grade glioma is predicated on IL-13Rα2 expression. (ISPNO 2022) - No abstract available

Preclinical • Brain Cancer • Glioma • Oncology • Solid Tumor • IL13

IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma. (PubMed, Pharmaceutics) - "In adults, glioblastoma (GBM) remains largely intractable, with a median survival of approximately 14 months despite standard clinical care of radiation and temozolomide...Direct intratumoral administration of GB-13 via convection-enhanced delivery (CED) significantly decreased tumor burden and resulted in prolonged survival in IL-13Rα2-upregulated orthotopic xenograft models of HGG. In summary, administration of GB-13 demonstrated a promising pharmacological response in HGG models both in vitro and in vivo in a manner strongly associated with IL-13Rα2 expression, underscoring the potential of this IL-13Rα2-targeted therapy in a subset of HGG with increased IL-13Rα2 levels."

Journal • Brain Cancer • Diffuse Midline Glioma • Glioblastoma • Glioma • Oncology • Pediatrics • Solid Tumor • IL13 • IL13RA2

IL-13Rα2 immunoconjugate targeted therapy for H3K27M-mutant midline gliomas (SNO 2021) - "Furthermore, we observed enhanced drug tissue retention and volume of distribution after CED, suggesting IL13.E13K-PE4E is capable of covering the target area and remaining at the site of infusion long enough to impart therapeutic effects. In summary, administration of IL13.E13K-PE4E demonstrated a potent pharmacological response in H3K27M DMG and GBM models both in vitro and in vivo in a manner strongly associated with IL13Rα2 expression, underscoring the potential of IL13Rα2 targeted therapy in a subset of these tumors."

Brain Cancer • Diffuse Midline Glioma • Glioblastoma • Glioma • Oncology • Pediatrics • Solid Tumor • IL13 • IL13RA2